NDAORALCAPSULE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TRICOR (MICRONIZED) (fenofibrate) by AbbVie is acid. Approved for dyslipidemia, hypertriglyceridemia, hypercholesterolemia and 1 more indications. First approved in 1993.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRICOR (micronized fenofibrate) is an oral fibrate that activates PPARα to reduce triglycerides and modify lipid profiles in patients with dyslipidemia, hypertriglyceridemia, and hypercholesterolemia. It works by increasing lipolysis, reducing apoprotein C-III production, and shifting LDL particles to larger, less atherogenic forms while raising HDL cholesterol. The drug also reduces serum uric acid by increasing urinary excretion.
LOE Approaching
TRICOR is in late decline with approaching loss of exclusivity, signaling possible team consolidation and shift toward generic support or portfolio rebalancing.
Mechanism of Action
acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human…
Indications (4)
Worked on TRICOR (MICRONIZED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.